MWNA
HRMY icon

Marshall Wace North America’s Harmony Biosciences HRMY Stock Holding History

Marshall Wace North America’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$223K Sell
5,819
-60,942
-91% -$1.96M ﹤0.01% 1301
2021
Q2 		$1.89M Sell
66,761
-22,186
-25% -$666K 0.01% 827
2021
Q1 		$2.94M Sell
88,947
-9,329
-9% -$327K 0.01% 707
2020
Q4 		$3.55M Buy
98,276
+3,696
+4% +$149K 0.02% 616
2020
Q3 		$3.21M Buy
+94,580
New +$3.45M 0.02% 474

Other funds holding HRMY

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
NP
Newlight Partners New York $3.9M AUM 96.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Marshall Wace North America's HRMY Position: Q3 2021 in Review

Marshall Wace North America reduced its Harmony Biosciences (HRMY) stake by 91% in Q3 2021, selling an estimated $1.96M and leaving 5,819 shares worth $223K. The position accounts for ﹤0.01% of the portfolio, ranked #1301.

Marshall Wace North America first reported a position in HRMY in Q3 2020 and has held it in 5 quarters since. The position peaked at $3.55M in Q4 2020. 102 funds tracked by Wall St. Rank hold HRMY as of Q3 2021.

  • Marshall Wace North America held 5,819 shares of Harmony Biosciences worth $223K as of Q3 2021.
  • Marshall Wace North America sold 60,942 Harmony Biosciences shares in Q3 2021, an estimated $1.96M.
  • Harmony Biosciences made up ﹤0.01% of Marshall Wace North America's portfolio in Q3 2021, its #1301 holding.
  • Marshall Wace North America first reported a position in Harmony Biosciences in Q3 2020 and has held it in 5 quarters since.
  • Marshall Wace North America's Harmony Biosciences position peaked at $3.55M in Q4 2020.
  • 102 funds tracked by Wall St. Rank held Harmony Biosciences as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.